These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29866419)

  • 1. Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information.
    Tefferi A; Gangat N; Mudireddy M; Lasho TL; Finke C; Begna KH; Elliott MA; Al-Kali A; Litzow MR; Hook CC; Wolanskyj AP; Hogan WJ; Patnaik MM; Pardanani A; Zblewski DL; He R; Viswanatha D; Hanson CA; Ketterling RP; Tang JL; Chou WC; Lin CC; Tsai CH; Tien HF; Hou HA
    Mayo Clin Proc; 2018 Oct; 93(10):1363-1374. PubMed ID: 29866419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model.
    Gangat N; Mudireddy M; Lasho TL; Finke CM; Nicolosi M; Szuber N; Patnaik MM; Pardanani A; Hanson CA; Ketterling RP; Tefferi A
    Am J Hematol; 2018 May; 93(5):691-697. PubMed ID: 29417633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS.
    Gu S; Xia J; Tian Y; Zi J; Ge Z
    BMC Cancer; 2021 Feb; 21(1):134. PubMed ID: 33549060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing.
    Patnaik MM; Lasho TL; Finke CM; Hanson CA; King RL; Ketterling RP; Gangat N; Tefferi A
    Am J Hematol; 2016 May; 91(5):492-8. PubMed ID: 26874914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of
    Farrukh F; Abdelmagid M; Mangaonkar A; Patnaik M; Al-Kali A; Elliott MA; Begna KH; Hook CC; Hogan WJ; Pardanani A; Litzow MR; Ketterling RP; Gangat N; Arber DA; Orazi A; He R; Reichard K; Tefferi A
    Haematologica; 2024 Aug; 109(8):2525-2532. PubMed ID: 38450522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
    Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
    Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical Characteristics and Prognosis of Myelodysplastic Syndromes Patients with
    Chen Y; Ji YR; Zhang JY; Qin WW; Liu CC; Liu L; Yan XQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):1173-1180. PubMed ID: 39192415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q).
    Tefferi A; Idossa D; Lasho TL; Mudireddy M; Finke C; Shah S; Nicolosi M; Patnaik MM; Pardanani A; Gangat N; Hanson CA; Ketterling RP
    Blood Cancer J; 2017 Dec; 7(12):658. PubMed ID: 29249799
    [No Abstract]   [Full Text] [Related]  

  • 9. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study.
    GenoMed4All consortium
    Lancet Haematol; 2023 Feb; 10(2):e117-e128. PubMed ID: 36436542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes.
    Kanagal-Shamanna R; Montalban-Bravo G; Sasaki K; Darbaniyan F; Jabbour E; Bueso-Ramos C; Wei Y; Chien K; Kadia T; Ravandi F; Borthakur G; Soltysiak KA; Routbort M; Patel K; Pierce S; Medeiros LJ; Kantarjian HM; Garcia-Manero G
    Cancer; 2021 Oct; 127(19):3552-3565. PubMed ID: 34161603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations and karyotype predict treatment response in myelodysplastic syndromes.
    Idossa D; Lasho TL; Finke CM; Ketterling RP; Patnaik MM; Pardanani A; Gangat N; Tefferi A
    Am J Hematol; 2018 Nov; 93(11):1420-1426. PubMed ID: 30152885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis and risk factors for ASXL1 mutations in patients with newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
    Yang L; Wei X; Gong Y
    Cancer Med; 2024 Jan; 13(1):e6871. PubMed ID: 38146893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analyzing Differences in Hematological and Immunological Characteristics Related to Common Gene Mutations in Myelodysplastic Syndromes.
    Yu J; Peng X; Wang R; Bai J; Li Y; Zhang L; Li L
    Discov Med; 2024 Jun; 36(185):1289-1297. PubMed ID: 38926115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome.
    Falantes JF; Márquez-Malaver FJ; Carrillo E; Culebras MG; Morales R; Prats C; Vargas MT; Caballero T; Rodríguez-Arbolí E; Espigado I; Pérez-Simón JA
    Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1059-e1066. PubMed ID: 36117041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis.
    Li F; Qin T; Li B; Qu S; Pan L; Zhang P; Sun Q; Cai W; Gao Q; Jiao M; Li J; Ai X; Ma J; Gale RP; Xu Z; Xiao Z
    Leukemia; 2024 Jun; 38(6):1334-1341. PubMed ID: 38714876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis.
    Huber S; Haferlach T; Meggendorfer M; Hutter S; Hoermann G; Baer C; Kern W; Haferlach C
    Leukemia; 2022 Dec; 36(12):2894-2902. PubMed ID: 36261576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
    Tang Y; Miao M; Han S; Qi J; Wang H; Ruan C; Wu D; Han Y
    Crit Rev Oncol Hematol; 2019 Jan; 133():74-83. PubMed ID: 30661660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
    Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A
    J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution.
    Lin CC; Hou HA; Chou WC; Kuo YY; Wu SJ; Liu CY; Chen CY; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Hsu SC; Ko BS; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Aug; 89(8):E109-15. PubMed ID: 24723457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome.
    Valcárcel D; Ademà V; Solé F; Ortega M; Nomdedeu B; Sanz G; Luño E; Cañizo C; de la Serna J; Ardanaz M; Marco V; Collado R; Grau J; Montoro J; Mallo M; Vallespí T
    J Clin Oncol; 2013 Mar; 31(7):916-22. PubMed ID: 23319689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.